Skip to main content

Global · Worldwide (from Santa Cruz, California)

Psychedelic trials and MAPS therapy model

Drug trials of 2021–2026, above all the MAPS-sponsored MDMA trials for PTSD, in which shaking was tallied as an adverse event while the MAPS therapy model welcomed spontaneous movement.

Period

2021–2026, the years of the trials and drug label read.

Today: Living

Evidence

Documented

The trial reports, the therapy framework, the psilocybin study and the esketamine label are each read and cited directly.

Lineage

Arises of itself

In the phase 3 trials of MDMA-assisted therapy for PTSD, shaking was counted as an adverse event. In MAPP2, published in 2023, fifty-three people had MDMA with therapy and fifty-one a placebo with therapy. Tremor was recorded in six of those on MDMA, 11.3 per cent, and in none on placebo. Eight on MDMA felt jittery, against none on placebo, and eight had chills, against one. MAPP1, published in 2021, has no tremor row, though muscle twitching appears in three of forty-six on MDMA and none on placebo. MAPS, the Multidisciplinary Association for Psychedelic Studies, funded MAPP2, and its public benefit corporation oversaw the collection, analysis and interpretation of the data.

The therapy's own framework, written by MAPS-trial therapists, reads the same body differently. It describes a 'permissive' attitude, 'even welcoming', towards 'intense emotional and embodied expression (e.g., spontaneous movement)'. Therapists stayed 'attuned to where the participant was within their window of tolerance'. The method relies on an 'inner healing intelligence', the 'organism's natural capacity to heal'. Its listed influences include Hakomi and Rolfing.

Elsewhere tremor is minor: one psilocybin study of thirteen people recorded a single 'hand tremor' event. The esketamine label lists tremor in 3 per cent of adults with treatment-resistant depression, against 1 per cent on placebo.

What kind of shaking

Sources

Where

Worldwide (from Santa Cruz, California)